Cite
HARVARD Citation
Ryan, C. et al. (n.d.). P674: UPDATED RESULTS OF A PHASE 1B STUDY OF IBRUTINIB (IBR) PLUS OBINUTUZUMAB (OBIN) IN PATIENTS WITH RELAPSED OR REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). HemaSphere. pp. 572-573. [Online].